Related Experiment Video
Updated: Mar 8, 2026
12:17
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
11.9K
Reducing Prosthesis-Patient Mismatch With Edwards Magna Prosthesis for Aortic Valve Replacement
Yuta Kume1, Tomoyuki Fujita, Satsuki Fukushima
1Department of Cardiac Surgery, National Cerebral and Cardiovascular Center.
Summary
The Carpentier-Edwards Perimount Magna and Magna Ease (CEPMs) bioprostheses effectively reduce prosthesis-patient mismatch (PPM) after aortic valve replacement. These devices offer excellent hemodynamics and low surgical risk, even in high-risk patients.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Medical Devices
Background:
- Prosthesis-patient mismatch (PPM) after aortic valve replacement (AVR) is linked to higher mortality.
- Evaluating novel bioprostheses is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy of Carpentier-Edwards Perimount Magna and Magna Ease (CEPMs) bioprostheses in mitigating PPM.
- To evaluate the hemodynamic performance and survival rates associated with CEPMs implantation.
Main Methods:
- A cohort of 282 patients undergoing AVR with CEPMs was analyzed.
- Patients were stratified into low-risk, medium-risk, and high-risk groups based on PPM risk (BSA/AnnD ratio).
- Outcomes including 30-day mortality, 5-year survival, explants, and severe PPM incidence were recorded.
Main Results:
- The 30-day mortality rate was low (0.4%).
- Five-year survival rates were high across all risk groups (92.3-94.8%).
- No severe PPM or explants due to valve deterioration were observed; hemodynamic parameters were favorable.
Conclusions:
- CEPMs demonstrate effectiveness in reducing PPM risk, including in high-risk patients.
- These bioprostheses are associated with excellent hemodynamic performance and low surgical risk.
- CEPMs represent a valuable option for AVR, improving patient outcomes and reducing PPM incidence.
